

Supplementary File 5

## Sensitivity analyses

<b>S Table-1: Sensitivity analyses on the primary outcome overall efficacy – effect sizes for each antidepressant versus placebo</b>				
Standardized mean differences and 95% credible intervals drug vs. placebo for efficacy, and ranks according to SUCRAs.				
Drug name	Standard analysis	SUCRA rank	Excluding 3 studies for early treatment	SUCRA rank
Reboxetine	-6.54 (-8.42, -4.65)	1	-6.54 (-8.41, -4.66)	1
Paroxetine	-2.70 (-3.46, 1.93)	2	-2.70 (-3.42, -1.97)	2
Doxepin	-2.60 (-3.35, -1.84)	3	-2.60 (-3.31, -1.88)	3
Duloxetine	-1.49 (-2.37, -0.62)	4	-1.62 (-2.25, -0.98)	4
Trazodone	-1.44 (-2.43, -0.46)	5	-	-
Nortriptyline	-1.22 (-1.99, 0.46)	6	-0.89 (-1.27, -0.50)	5
<b><u>Citalopram</u></b>	-0.59 (-1.14, -0.04)	7	-0.66 (-1.07, -0.25)	7
<b><u>Sertraline</u></b>	-0.61 (-1.47, 0.25)	8	-0.78 (-1.12, -0.45)	6
Placebo	<i>Reference</i>	9	<i>Reference</i>	8
Nefiracetam	0.05 (-0.39, 0.49)	10	0.05 (-0.32, 0.42)	9
Fluoxetine	0.51 (-0.17, 1.19)	11	0.63 (-0.05, 1.23)	10

**S-Table 2: Sensitivity analyses on the secondary outcome acceptability – effect sizes for each antidepressant versus placebo**

Standardised mean differences and 95% credible intervals drug vs. placebo for efficacy, and ranks according to SUCRAs

Drug name	Standard analysis	SUCRA rank	Excluding 3 studies for early treatment	SUCRA rank
Paroxetine	0.09 (0.00, 1.83)	1	0.09 (0.00, 1.83)	1
Placebo	<i>Reference</i>	2	<i>Reference</i>	2
<b><u>Sertraline</u></b>	1.09 (0.35, 3.43)	3	1.09 (0.35, 3.43)	4
<b><u>Nortriptyline</u></b>	1.10 (0.38, 3.23)	4	1.09 (0.37, 3.26)	3
Trazodone	1 (0.02, 54.83)	5	-	
Reboxetine	0.94 (0.02, 50.30)	5	0.94 (0.02, 50.30)	5
Nefiracetam	1.42 (0.46, 4.40)	7	1.42 (0.46, 4.40)	6
Duloxetine	1.93 (0.05, 69.28)	8	1.93 (0.05, 69.28)	7
Doxepin	2.35 (0.63, 8.73)	9	2.35 (0.63, 8.73)	8
Fluoxetine	2.52 (0.81, 7.84)	10	2.47 (0.69, 8.87)	9
Citalopram	3.42 (0.73, 15.91)	11	3.42 (0.73, 15.91)	10